Table 1.

Markers significantly associated with OS under ICI in the discovery cohort YTMA471; Overall Survival, OS; Immune Checkpoint Inhibitors, ICI; Yale tissue microarray, YTMA; AOI, Area of Illumination

MARKERS ASSOCIATED WITH OS
Compartment/AOI	N	Marker	Univariate HR (95% CI)	P-value	Multivariate HR (95% CI)	P-value
CK (panCK+)	54	S100B	0.71 (0.53, 0.96)	0.017	0.70 (0.51, 0.95)	0.041
		EpCAM	1.31 (1.01,1.69)	0.035	1.24 (0.91, 1.68)	0.20
		ARG1	1.52 (1.06, 2.19)	0.026	1.34 (0.91,1.98)	0.14
		CD66b	1.32 (1.13, 1.54)	0.001	1.25 (1.04, 1.50)	0.020
Immune Stroma (panCK−/CD45+/CD68+)	54	S100B	0.56 (0.40,0.78)	<0.001	0.56 (0.7,0.84)	0.006
		EpCAM	1.32 (1.02,1.70)	0.034	1.41 (1.09, 1.82)	0.054
		CD66b	1.31 (1.06,1.60)	0.016	1.25 (1.04, 1.52)	0.045
CD45 (panCK−/CD45+/CD68−)	52	PD-L1	0.41 (0.24, 0.69)	<0.001	0.41 (0.22, 0.75)	0.005
		S100B	0.54 (0.38,0.77)	<0.001	0.47 (0.33, 0.68)	<0.001
		P44/42 MAPK ERK1/2	0.35 (0.15,0.80)	0.019	0.43 (0.17, 1.09)	0.094
		EGFR	0.50 (0.28, 0.90)	0.014	0.48 (0.24, 0.95)	0.023
		CD66b	1.26 (1.03, 1.54)	0.034	1.20 (0.96, 1.51)	0.13
CD68 (panCK−/CD68+)	49	S100B	0.60 (0.43, 0.84)	0.002	0.59 (0.38,0.93)	0.020
		EpCAM	1.29 (1.02, 1.64)	0.034	1.40 (1.02, 1.93)	0.041
		Phospho-JNK (T183/Y185)	1.44 (1.02, 2.05)	0.048	1.56 (1.04,0.036)	0.13
		P44/42 MAPK ERK1/2	0.31 (0.13, 0.75)	0.013	0.34 (0.12,0.96)	0.047
		CD66b	1.37 (1.12, 1.67)	0.004	1.32 (1.08, 1.62)	0.009

Note: Bold terms have P values that are significant after adjusting for multiple comparisons and/or after controlling for clinical prognostic factors in the multivariate analysis. Overall survival (OS) was calculated from the start of immunotherapy until death or censoring.